טוען...
Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein
Hepatocellular carcinoma (HCC) represents ~90% of primary liver cancers and constitutes a major global health problem. Since a decade ago, the management of advanced disease that cannot be locally treated has mainly been based on multi-targeted antiangiogenic therapies. Some have demonstrated improv...
שמור ב:
| הוצא לאור ב: | J Hepatocell Carcinoma |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Review
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6219272/ https://ncbi.nlm.nih.gov/pubmed/30464931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S157413 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|